CD19 is expressed on normal and neoplastic B cells and is a promising target for immunotherapy. However, there is still an unmet need to further develop novel therapeutic drugs for the treatment of the refractory/relapsing human CD19 + tumors. We have developed a diphtheria toxin-based anti-human CD19 immunotoxin for targeting human CD19 + tumors. We have constructed three isoforms of the CD19 immunotoxin: monovalent, bivalent, and foldback diabody. In vitro binding affinity and efficacy analysis demonstrated that the bivalent isoform had the highest binding affinity and in vitro efficacy. The in vivo efficacy of the CD19 immunotoxins was assessed using human CD19 + JeKo-1 tumor-bearing NOD/SCID IL-2 receptor c À/À (NSG) mouse model. In these animals, CD19 immunotoxins significantly prolonged the median survival from 31 days in controls to 34, 36, and 40 days in animals receiving the monovalent isoform, foldback diabody isoform, and bivalent isoform, respectively. The bivalent CD19 immunotoxin is a promising therapeutic drug candidate for targeting relapsing/refractory human CD19 + tumors.
Introduction
CD19 is a 95-kDa transmembrane glycoprotein which is widely expressed on both normal and malignant B cells including chronic lymphatic lymphoma, nonHodgkin's B-cell lymphoma, and B-cell acute lymphoblastic leukemia (Turtle et al., 2016; Vallera et al., 2005) . CD19 is known as a promising immunotherapy target. Anti-human CD19 mAb drugs are already in the clinic or in clinical trials .
However, effective antibody treatment requires the contributions of host effector mechanisms such as complement and NK cells. In contrast, immunotoxins are able to eliminate target cells even when host effector mechanisms are compromised due to chemotherapeutic agents or malnutrition. Some chemical-conjugated anti-human CD19 immunotoxins are already in clinical trial . However, these have varied degree of effectiveness and production difficulties (Vallera et al., 2005; Wayne et al., 2014) . CD22-CD19-bispecific recombinant immunotoxin is in clinical trials (Bachanova et al., 2015; Vallera et al., 2005) . However, its efficacy is dependent on target cells expressing CD22 and CD19 simultaneously. Previous attempts to produce a CD19-specific recombinant immunotoxin have been unsuccessful (Du et al., 2008) . We hypothesize that this was due to a suboptimal expression system. In this study, we developed a recombinant anti-human CD19 immunotoxin using unique diphtheria toxin-resistant yeast Pichia Pastoris expression system. The in vitro binding affinity and efficacy of the CD19 immunotoxin were assessed using human CD19
+ mantle cell lymphoma cell line JeKo-1. The in vivo efficacy of the CD19 immunotoxin was characterized using human CD19 + tumor-bearing NSG mouse model.
Materials and methods

Cell lines and antibodies
Human CD19
+ mantle cell lymphoma cell line JeKo-1 (cat# CRL-3006) and human CD19
À cell line CCRF-CEM (cat# CCL-119) were purchased from ATCC (Manassas, VA, USA). Human CD19 À cell line M14
and MD-MBA-231 were generously provided by Soldano Ferrone (Massachusetts General Hospital). mAbs used in this study are listed in Table 1 .
DNA construction
As shown in Fig. 1 , anti-human CD19 immunotoxins were constructed using DT390 (Woo et al., 2002) and the codon-optimized scFv (FMC63) nucleotide sequences ( Figure 2 , Nicholson et al., 1997) . A strategy previously used to generate the anti-human CCR4 immunotoxin (Wang et al., 2015) was applied to construct the anti-human CD19 immunotoxins. DT390 and scFv (FMC63) or bi-scFv (FMC63) are connected by a G 4 S (four glycines and one serine residue) linker. The two scFv (FMC63) of the bivalent immunotoxin are joined by (G 4 S) 3 linker. Six histidines (6x His tag) were added to the C terminus of each construct to facilitate protein purification. To construct DT390-scFv (FMC63), the codon-optimized scFv (FMC63) was synthesized by GenScript and cloned into pwPICZalpha-DT390 (Wang et al., 2011 (Wang et al., , 2015 between NcoI and EcoRI sites, yielding the final construct DT390-scFv (FMC63) in pwPICZalpha. To construct DT390-BiscFv (FMC63), the first scFv (FMC63) was amplified using PCR primers FMC-Nco and digested using BamHI. The VH portion was amplified using PCR primers BgL-FMC carrying BglII site + FMC-Bam1 and digested using Bgl II. The BamHI-digested VL portion and Bgl II-digested VH were ligated together for 4 h at room temperature as PCR template to amplify the scFv (FMC63) with short linker (one G 4 S) for constructing the single-chain foldback diabody isoform following the construction procedure for DT390-BiscFv (FMC63). All PCR primers that were used are listed in Table 2. CD19 immunotoxin expression in the diphtheria toxin-resistant yeast Pichia Pastoris expression system and purifications were performed as previously described (Peraino et al., 2013a; Wang et al., 2011) . Western blot analysis, binding and blocking analysis by flow cytometry were all performed as previously described (Peraino et al., 2013a ) using a human CD19 + mantle cell lymphoma cell line JeKo-1. DT390 was used as negative control for in vitro functional analysis. C21 immunotoxin (a nonrelated DT390-based immunotoxin) was used as negative control for in vivo efficacy characterization. Both DT390 and C21 immunotoxin were also expressed using yeast Pichia Pastoris expression system in our laboratory. Isolation of human PBMC, in vitro binding and depletion analysis of the CD19 immunotoxins to human blood, or PBMC with flow cytometry was performed as previously described (Wang et al., 2015) .
In vitro efficacy analysis
In vitro efficacy of the CD19 immunotoxins was assessed using CellTiter-GloÒ Luminescent Cell Viability Assay (Promega, cat# G7571) to human CD19 + mantle cell lymphoma cell line JeKo-1. Briefly, the 
In vivo efficacy analysis
The breeding pairs of NSG mice were purchased from Jackson laboratories (Bar Harbor, Maine) and bred in our rodent barrier facilities. All animal experiments were approved by Massachusetts General Hospital (MGH) Institutional Animal Care and Use Committee (IACUC). The NSG mice were divided into following groups: (a) C21 immunotoxin control group (a nonrelated diphtheria toxin-based immunotoxin as negative control) (n = 7); (b) monovalent CD19 immunotoxin group (n = 7); (c) bivalent CD19 immunotoxin group (n = 7); and (d) single-chain foldback diabody CD19 immunotoxin group (n = 7). All animals were injected Table 2 . PCR primers used in this study. IV with 10 million of human CD19 + mantle cell lymphoma cells (JeKo-1) via the tail vein. The immunotoxin was injected IP from day 0 on at 100 lgÁkg À1 , BID for four consecutive days as one course, four courses in total, and three-day break between any two courses. The injected animals were observed daily for signs and symptoms of illness and scored twice weekly based on the parameters as previously reported by our laboratory (Peraino et al., 2013b and Wang et al., 2015) . In addition, to assess whether the CD19 immunotoxin is toxic to the animals, NSG mice (n = 2) injected with the bivalent CD19 immunotoxin only were also included as control.
FMC-Nco
Statistical analysis
All p values were calculated using log-rank (MantelCox) test of Prism. p < 0.05 was considered as significant. IC 50 was determined using nonlinear regression (curve fit) of Prism.
Results
Expression and purification of the CD19 immunotoxin
As shown in Fig. 1 , monovalent, bivalent, and singlechain foldback diabody versions of the anti-human CD19 immunotoxins were constructed to find the isoform with the highest binding affinity and greatest ability to deplete human CD19 + cells. The codon-optimized anti-human CD19 scFv (FMC63) DNA (Fig. 2) (Nicholson et al., 1997) was cloned into the C terminus of the DT390-containing yeast Pichia Pastoris expression vector pwPICZalpha-DT390 between the NcoI and EcoRI sites (Wang et al., 2015) . A 6xHis tag was added to the C terminus of each immunotoxin isoform to facilitate the purification. The DT390 domain was genetically linked to the scFv (FMC63) domain by a linker containing four glycine residues and a serine residue (G 4 S). For the monovalent and bivalent versions, the VL and VH were linked together by a long linker (G 4 S) 3 to generate the scFv (FMC63). For the single-chain foldback diabody isoform, the VL and VH were linked by a short linker G 4 S. The two scFv (FMC63) of the bivalent and the single-chain foldback diabody isoforms were also joined by a long linker (G 4 S) 3 .
The CD19 immunotoxins were expressed using unique diphtheria toxin-resistant yeast Pichia Pastoris (Liu et al., 2003) expression system in 1-L Erlenmeyer flasks. The CD19 immunotoxins were captured using a Ni-Sepharose fast flow resin and further purified using strong anion-exchange resin. The final purification yield was~15 mg per liter for the monovalent and 6 mg per liter for the bivalent and~2 mg per liter for the single-chain foldback diabody CD19 immunotoxins of the original harvested supernatant. The purified anti-human CD19 immunotoxins were analyzed by SDS/PAGE (Fig. 3A) and western blot using a mouse anti-6xHis mAb (Fig. 3B ) and a mouse antidiphtheria toxin mAb (Fig. 3C) . SDS/PAGE and western blot analysis demonstrated that the three versions of the CD19 immunotoxins were expressed and purified with expected molecular weight of 70.09 kDa for the monovalent isoform, 96.95 kDa for the bivalent isoform, and 95.69 kDa for the single-chain foldback diabody isoform.
3.2 Binding affinity analysis of the CD19 immunotoxins using flow cytometry CD19 immunotoxins were designed to deplete human CD19 + cells via binding of the anti-human CD19 scFv (FMC63) domain of the immunotoxins on the CD19 receptor of the CD19 + cells. Following the internalization, the released DT390 domain functions to inhibit protein synthesis resulting in the cell death (Murphy, 2011) ; therefore, the first step to characterize the CD19 immunotoxins was to analyze their binding affinity to human CD19 receptor. The anti-human CD19 immunotoxins were biotin-labeled for the binding analysis to human CD19 + JeKo-1 cells using flow cytometry. As shown in Fig. 4A , monovalent (left panel), bivalent (middle panel), and single-chain foldback diabody (right panel) CD19 immunotoxins bound to the human CD19 in a dose-dependent manner. The binding affinity was quantified by the dissociation constant (K D ) for each CD19 immunotoxin isoform using mean fluorescence intensity (MFI) (Peraino et al., 2013a) . The foldback diabody isoform (K D = 11.22 nM, Fig. 4D ) bound stronger than the monovalent isoform (K D = 47.42 nM, Fig. 4B ). However, the bivalent isoform exhibited the highest binding affinity (K D = 4.59 nM, Fig. 4C ).
The binding specificity of the CD19 immunotoxins was further analyzed by blocking the binding of the parent anti-human CD19 mAb (FMC63) to its receptor on human CD19 + JeKo-1 tumor cells. As shown in Fig. 5 , monovalent (left panel), bivalent (middle panel), and single-chain foldback diabody (right panel) CD19 immunotoxins blocked the binding of antihuman CD19 mAb (FMC63) to the JeKo-1 cells in a dose-dependent fashion. The data strongly suggest that the CD19 immunotoxins bind specifically to the human CD19 receptor.
In vitro efficacy analysis of the CD19 immunotoxin
In vitro efficacy of the CD19 immunotoxins was assessed using CellTiter-GloÒ Luminescent Cell Viability Assay (Promega) in a human CD19 tumor cell line. As shown in Fig. 6 , all of the three CD19 immunotoxin isoforms (monovalent, bivalent, and foldback diabody) were effective. The foldback diabody isoform (IC 50 = 1.7 9 10 À11 M) was better than the monovalent isoform (IC 50 = 2 9 10
while the bivalent isoform (IC 50 = 2 9 10 À12 M) was greatest. This findings correlate well with the corresponding binding affinity analysis. 
In vitro binding and depletion analysis of the CD19 immunotoxins to human blood or PBMC
CD19 is expressed on normal human B cells. To further characterize the CD19 immunotoxins, we performed in vitro binding and depletion analyses of the CD19 immunotoxins in human blood or PBMC. As shown in Fig. 7A , all three isoforms of the biotinylated CD19 immunotoxins bound to CD19 + human blood in a dose-dependent fashion. The foldback diabody isoform bound more strongly than the monovalent isoform, while the bivalent isoform was best, which is consistent with the previous binding analysis using the human CD19 + JeKo-1 cell line. We then further performed in vitro depletion analysis in CD19 + human PBMC using the CD19 immunotoxins. As shown in Fig. 7B, CD19 + human PBMC was depleted in a dose-dependent manner following incubation of the CD19 immunotoxin with the human PBMC for 48 h. The bivalent and foldback diabody isoforms were better than the monovalent isoform, while the bivalent isoform was the most effective.
Off-target analysis of the CD19 immunotoxin
To rule out the off-target effect of the CD19 immunotoxin, three human CD19 À tumor cell lines were analyzed with biotinylated bivalent human CD19 immunotoxin using flow cytometry: (a) CCRF-CEM, (b) M14, and (c) MD-MBA-231. The results demonstrated that there was no binding activity with the three human CD19 À tumor cell lines (Fig. 8A) . The viability of the three human CD19 À tumor cell lines was also analyzed by flow cytometry using 7-aminoactinomycin D and Annexin V staining following incubation with the bivalent CD19 immunotoxin for 18 h. Their viability was not affected by this treatment (Fig. 8B) . To further rule out the off-target effect of the CD19 immunotoxin, we also analyzed the human CD19 . The results demonstrated that there was no effect on human CD19
À PBMC populations (Fig. 8C ).
In vivo efficacy analysis of the CD19 immunotoxins
In vivo efficacy of the CD19 immunotoxins was assessed using human CD19 + JeKo-1 mantle cell lymphoma-bearing immunodeficient NSG mouse model. Human CD19 + JeKo-1 cells (1 9 10 7 ) were injected IV and the CD19 immunotoxins were injected IP at 100 lgÁkg À1 , BID, for four consecutive days as one course, four courses in total, and three-day break between any two courses. As shown in Fig. 9 , the C21 immunotoxin was included as a negative control (n = 7). These data demonstrated that all three CD19 immunotoxin isoforms prolonged animal survival significantly from a median of 31 days in the negative control group (C21 immunotoxin) to 34 days in the monovalent isoform treatment group (n = 7, p < 0.0001), to 36 days in the foldback diabody isoform treatment group (n = 7, p < 0.0001), to 40 days in the bivalent isoform treatment group (n = 7, p < 0.0001) (Fig. 9) . Mice receiving the CD19 immunotoxin only did not show any toxicity (data not shown). All animals injected with the human CD19 + JeKo-1 cells succumbed to tumors (data not shown).
Discussion
Several attempts to develop recombinant anti-human CD19 immunotoxins have been unsuccessful (Du et al., 2008) . We speculate that the use of an inappropriate expression system was part of the problem. Diphtheria toxin-resistant yeast Pichia Pastoris expression system is suitable for DT390-based immunotoxin development. We speculate that eukaryotic expression systems such as yeast Pichia Pastoris expression system might be better than prokaryotic expression system such as E. coli. Based on our previous experience, the foldback diabody immunotoxin isoform is superior to both bivalent and monovalent isoforms in terms of the in vitro binding affinity and efficacy (Kim et al., 2007; Wang et al., 2015) . However, the foldback diabody isoform in this study did not improve the in vitro binding affinity and efficacy comparing with the bivalent isoform. Therefore, it is case by case for the immunotoxin development to find the best isoform (Wei et al., 2014) .
The in vivo dosing schedule (Fig. 9 ) in this study has not been optimized. Our focus was simply to assess whether the CD19 immunotoxin functions in vivo. There is still room to increase the dose and duration to improve the animal survival. It is also necessary to characterize the in vivo efficacy further using established xenograft tumor-bearing NSG mouse model. Furthermore, analyzing the residue tumor cells in vitro to determine whether they are still sensitive to the CD19 immunotoxin is warranted. If they remain sensitive, higher doses and multiple course of treatment could improve animal survival further.
Conventional chemotherapy and targeted mAb therapy have contributed significantly to the treatment for CD19 + B-cell leukemia/lymphoma. However, there is still an unmet need to develop novel targeted therapies against the relapsing/refractory patients with CD19 Fig. 9 . In vivo efficacy analysis of the anti-human CD19 immunotoxins. NSG mice were injected IV with 1.0 9 10 7 human CD19 + JeKo-1 lymphoma cells and treated from day 0 on with the anti-human CD19 immunotoxin (IP injection) at 100 lgÁkg À1 BID for four consecutive days as one course, four courses in total, and three-day break between any two courses. (a) C21 immunotoxin control group (a nonrelated DT390-based immunotoxin as negative control) (n = 7, green curve) with a median survival time of 31 days; (b) monovalent anti-human CD19 immunotoxin group (n = 7, blue curve) with a median survival time of 34 days; (c) bivalent anti-human CD19 immunotoxin group (n = 7, red curve) with a median survival time of 40 days; (d) single-chain foldback diabody anti-human CD19 immunotoxin group (n = 7, purple curve) with a median survival time of 36 days. The schedule of drug and tumor cell injection is pictured in the schematic below the survival curve. The vertical arrows indicate the days on which the tumor cells or anti-human CD19 immunotoxins were injected.
leukemia/lymphoma following the chemotherapy and targeted mAb therapy. We believe that CD19 immunotoxin will provide a novel alternative therapy for the refractory/relapsing CD19 + tumor patients.
